This week, Jonathan is joined by Fredrik Schjesvold, Head of the Oslo Myeloma Center Oslo University Hospital, Head of the Norwegian myeloma association, and President of the Nordic Myeloma Study Group.   Timestamps:      (00:00)-Introduction   (04:24)-Research into melflufen  (07:14)- Ide-cel CAR T-cell therapy  (09:40)-Predictors of overall survival  (12:15)-Innovative therapies for refractory myeloma  (14:04)-Bi-specific antibodies  (16:42)-Global guidelines for myeloma  (22:00)-Healthcare economics  (25:45)-Antibody-based therapies  (29:38)- Latest research into amyloidosis  (34:23)-Recent breakthroughs in myeloma  (38:06)-Fredrik's three wishes for healthcare     

Ver todos los episodios